Taro Pharmaceutical Industries Ltd. (NYSE:TARO) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Brokerages have set a one year consensus price target of $120.00 for the company and are expecting that the company will post $1.96 earnings per share for the current quarter, according to Zacks. Zacks has also given Taro Pharmaceutical Industries an industry rank of 107 out of 255 based on the ratings given to related companies.

A number of brokerages have weighed in on TARO. TheStreet raised Taro Pharmaceutical Industries from a “c+” rating to a “b-” rating in a research report on Monday, June 4th. Zacks Investment Research raised Taro Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $129.00 price target for the company in a research report on Saturday, May 26th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $120.00 price target on shares of Taro Pharmaceutical Industries in a research report on Friday, August 10th.

Shares of NYSE:TARO opened at $100.76 on Tuesday. Taro Pharmaceutical Industries has a fifty-two week low of $93.01 and a fifty-two week high of $128.46. The stock has a market capitalization of $4.06 billion, a price-to-earnings ratio of 16.30 and a beta of 0.48.

Taro Pharmaceutical Industries (NYSE:TARO) last announced its quarterly earnings results on Thursday, August 9th. The company reported $1.71 earnings per share for the quarter, missing analysts’ consensus estimates of $2.33 by ($0.62). Taro Pharmaceutical Industries had a return on equity of 11.73% and a net margin of 34.18%. The company had revenue of $154.62 million during the quarter, compared to analyst estimates of $179.54 million. sell-side analysts expect that Taro Pharmaceutical Industries will post 7.65 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in TARO. Acadian Asset Management LLC increased its stake in shares of Taro Pharmaceutical Industries by 136.8% in the second quarter. Acadian Asset Management LLC now owns 235,930 shares of the company’s stock worth $27,295,000 after purchasing an additional 136,287 shares during the period. Jupiter Asset Management Ltd. bought a new position in shares of Taro Pharmaceutical Industries in the first quarter worth about $4,038,000. Robeco Institutional Asset Management B.V. bought a new position in shares of Taro Pharmaceutical Industries in the second quarter worth about $3,838,000. Renaissance Technologies LLC increased its stake in shares of Taro Pharmaceutical Industries by 9.8% in the second quarter. Renaissance Technologies LLC now owns 287,000 shares of the company’s stock worth $33,203,000 after purchasing an additional 25,600 shares during the period. Finally, Boston Partners bought a new position in shares of Taro Pharmaceutical Industries in the second quarter worth about $2,723,000. 10.41% of the stock is owned by institutional investors.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.

Featured Article: Growth Stocks

Get a free copy of the Zacks research report on Taro Pharmaceutical Industries (TARO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.